Dropping with the temps: Cool deals on CST mAbs | Learn More >>
MSH6 (L990) Antibody
Primary Antibodies

MSH6 (L990) Antibody #3996

This product is discontinued

We recommend the following alternatives

# Product Name Application Reactivity
  • WB
  • IF

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

MSH6 (L990) Antibody detects endogenous levels of total MSH6 protein.

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human MLH6. Antibodies are purified using protein A and peptide affinity chromatography.

The DNA mismatch repair system (MMR) repairs post-replication DNA, inhibits recombination between nonidentical DNA sequences, and induces both checkpoint and apoptotic responses following certain types of DNA damage (1). MSH2 (MutS homologue 2) forms the hMutS-α dimer with MSH6 and is an essential component of the mismatch repair process. hMutS-α is part of the BRCA1-associated surveillance complex (BASC), a complex that also contains BRCA1, MLH1, ATM, BLM, PMS2 proteins, and the Rad50-Mre11-NBS1 complex (2). Mutations in MSH6 and other MMR proteins have been found in a large proportion of hereditary nonpolyposis colorectal cancer (Lynch Syndrome), the most common form of inherited colorectal cancer in the Western world (3). Mutations in MSH6 have been shown to occur in glioblastoma in response to temozolomide therapy and to promote temozolomide resistance (4).

  1. O'Brien, V. and Brown, R. (2006) Carcinogenesis 27, 682-92.
  2. Wang, Y. et al. (2000) Genes Dev 14, 927-39.
  3. Plotz, G. et al. (2006) J Mol Histol 37, 271-83.
  4. Yip, S. et al. (2009) Clin Cancer Res 15, 4622-9.
Entrez-Gene Id
Swiss-Prot Acc.
For Research Use Only. Not For Use In Diagnostic Procedures.

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

Upstream / Downstream


Explore pathways related to this product.